All In Biotech

Drug Trial Radar · NCT06577376

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Simmitinib or Irinotecan Liposomes Combined With DP303c Injection in the Treatment of HER2 Expressing Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Aug 26, 2024

Primary completion

Aug 26, 2026

Study completion Aug 26, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with simmitinib; Cohort 2 includes dose escalation/dose extension of DP303c combined with irinotecan liposomes, as well as RCT stage of DP303c combined with irinotecan liposomes.

Conditions

  • Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
  • Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
  • Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past

Interventions

  • DP303cDrug

    DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker

  • Simmitinib tabletsDrug

    A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)

  • Irinotecan liposomesDrug

    A chemotherapy

  • Paclitaxel or docetaxel or irinotecanDrug

    Paclitaxel or docetaxel or irinotecan is used as a control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT) occurrence and incidenceTime frame: Up to approximately 36 months after the first participant is enrolled
  2. Adverse events (AE) occurrence and incidenceTime frame: Up to approximately 36 months after the first participant is enrolled
  3. Objective response rate (ORR) per RECIST 1.1Time frame: Up to approximately 36 months after the first participant is enrolled
  4. Serious adverse events (SAE) occurrence and incidenceTime frame: Up to approximately 36 months after the first participant is enrolled

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.